Argenica Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Other Revenue	3.08	2.6	1.75	0.26	0.3	-
Revenue	3.08	2.6	1.75	0.26	0.3	-
Revenue Growth (YoY)	13.03%	48.46%	575.38%	-12.49%	-	-
Gross Profit	3.08	2.6	1.75	0.26	0.3	-
Selling, General & Admin	2.51	2.11	1.86	1.43	0.64	0.09
Research & Development	6.11	6.02	4.31	2.5	0.42	0.57
Operating Expenses	8.75	8.27	6.62	4.35	1.33	0.66
Operating Income	-5.67	-5.67	-4.87	-4.09	-1.03	-0.66
Interest Expense	-0	-0	-0	-0	-0	-
Interest & Investment Income	0.41	0.19	0.06	0	0	0
Pretax Income	-5.26	-5.48	-4.82	-4.09	-1.03	-0.66
Income Tax Expense	-	-	-	-	0	-
Net Income	-5.26	-5.48	-4.82	-4.09	-1.03	-0.66
Net Income to Common	-5.26	-5.48	-4.82	-4.09	-1.03	-0.66
Shares Outstanding (Basic)	117	104	74	74	35	17
Shares Outstanding (Diluted)	117	104	74	74	35	17
Shares Change (YoY)	46.14%	40.29%	-	108.80%	112.54%	-
EPS (Basic)	-0.04	-0.05	-0.07	-0.06	-0.03	-0.04
EPS (Diluted)	-0.04	-0.05	-0.07	-0.06	-0.03	-0.04
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-184.14%	-218.30%	-278.59%	-1579.49%	-347.76%	-
Profit Margin	-170.72%	-210.92%	-275.16%	-1578.84%	-347.72%	-
EBIT	-5.67	-5.67	-4.87	-4.09	-1.03	-0.66
EBIT Margin	-184.14%	-218.30%	-278.59%	-	-	-
Revenue as Reported	3.49	2.79	1.81	0.26	0.3	0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.